Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP006: Gut homing adipose tissue T-cells might influence intestinal barrier function in Crohn’s disease and obesity
Year: 2016
Source: ECCO'16 DOP
Authors: Jödicke L.
Crohn's Disease, lymphocyte
Files: 1
DOP006: Research gaps in diet and nutrition in Inflammatory Bowel Disease. A topical review by ECCO
Year: 2017
Source: ECCO'17 Barcelona
Authors: Gerasimidis K.
environmental factors, Macrobiota, Anaemia, iron deficiency, Exclusive enternal nutrition, FODMAP
Files: 1
DOP007: Crohn Disease exclusion diet and partial enteral nutrition (CDED+PEN) vs exclusive enteral nutrition (EEN): Microbiome changes of a randomised clinical trial (RCT) in paediatric CD: Remission is associated with similar structural + functional profiles
Year: 2017
Source: ECCO'17 Barcelona
Authors: Van Limbergen J.
Microbiota, Exclusive enteral nutrition
Files: 1
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha resistant Inflammatory Bowel Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Bor Renata
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP007: Interleukin-10 inhibits human IFN#CHR:gamma_LOWER# and IL-17-producing T helper cells indirectly by controlling antigen-presenting cell function
Year: 2016
Source: ECCO'16 DOP
Authors: Veenbergen S.
dendritic cell, Crohn's Disease, lymphocyte, mucosal immunology
Files: 1
DOP008: Dietary manipulation of the healthy human and Colitic murine gut microbiome by CD-TREAT diet and exclusive enteral nutrition; a proof of concept study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Gerasimidis K.
environmental factors, Microbiota, Exclusive enternal nutrition
Files: 1
DOP008: Human intestinal V#CHR:delta_LOWER#2+ T-cells acquire antigen-presenting potency upon exposure to microbial phosphoantigen: modulation by mucosal inflammation and vedolizumab therapy
Year: 2016
Source: ECCO'16 DOP
Authors: McCarthy N.
Crohn's Disease, Ulcerative Colitis, Lymphocyte, mucosal immunology, vedolizumab
Files: 1
DOP008: Safety of adalimumab in children and adolescents with Moderate to Severe Crohn’s Disease: Interim results of the CAPE registry
Year: 2018
Source: ECCO'18 Vienna
Authors: Turner Dan
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP009: An autoimmunity-associated variant in PTPN22 protects from disease onset in mouse models of colitis
Year: 2016
Source: ECCO'16 DOP
Authors: Spalinger M.
cancer in IBD, IBD, microbiota, lymphocyte, genetics
Files: 1
DOP009: Choice of corticosteroids or exclusive enteral nutrition as the first induction of remission therapy does not affect disease behavior within two years of diagnosis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Cohen-Dolev N.
Crohn's disease, Corticosteroid, Exclusive enteral nutrition
Files: 1
DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for Inflammatory Bowel Disease: A multicentre consortium propensity score–matched analysis
Year: 2018
Source: ECCO'18 Vienna
Authors: Dulai Parambir S
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP010: ECCO Topical Review on Transitional Care in Inflammatory Bowel Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: van Rheenen P.
Paediatric, Transfer, Transition
Files: 1
DOP010: Frequency and Characteristics of Infusion Reactions during Biosimilar Infliximab Treatment in Inflammatory Bowel Diseases: results from Central European nationwide cohort
Year: 2016
Source: ECCO'16 DOP
Authors: Balint A.
anti-TNF agents, biosimilars, Ulcerative Colitis, Crohn's Disease, trough levels
Files: 1
DOP011: Early immunomodulator exposure and the long-term outcome of Crohn’s disease: target for changing the natural history?
Year: 2016
Source: ECCO'16 DOP
Authors: Jeuring S.
Thiopruines (AZA / MP), Crohn's Disease
Files: 1
DOP011: Genotype-Phenotype association analysis of Inflammatory Bowel Disease in 6,395 East Asian subjects: Results from the international IBD Genetics Consortium
Year: 2018
Source: ECCO'18 Vienna
Authors: Abedian Shifteh
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP011: Risk of opportunistic infection in healthcare personnel with Inflammatory Bowel Disease: A case-control study of the GETAID
Year: 2017
Source: ECCO'17 Barcelona
Authors: Amiot A.
Clostridium difficile, CMV, EBV, Morbidity, Tuberculosis
Files: 1
DOP012: Disease demarcation in Ulcerative Colitis is associated with different patterns of gene expression
Year: 2018
Source: ECCO'18 Vienna
Authors: Argmann Carmen
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP012: Do ulcerative colitis patients treated withcorticosteroids at diagnosis really have a more aggressive disease course?
Year: 2016
Source: ECCO'16 DOP
Authors: Bertani L.
Ulcerative Colitis, corticosteroids
Files: 1
DOP012: Impact on clinical practice of Epstein-Barr virus infection in patients with Inflammatory Bowel Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: de Francisco R.
Thiopurines, EBV, Lymphoma
Files: 1
DOP013: A 104 week mucosal healing assessment of symptomatic small bowel Crohn’s disease
Year: 2016
Source: ECCO'16 DOP
Authors: Hall B.
anti-TNF, capsule endoscpy, Crohn's Disease, mucosal healing
Files: 1